ClinicalTrials.gg

Program

exagamglogene autotemcel

Also written as “CTX001”, “Exa-cel” and “CTX001 With and Without Iron”.

Its studies are mostly in beta-Thalassemia · Anemia, Sickle Cell · Renal Insufficiency, Chronic · Anemia, led by 2 companies.

Furthest: phase 3, since Aug 29, 20189 company-led studies, 6 open or runningNext primary completion: Jun 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals74 open or runningphase 3since Aug 29, 2018Aug 29, 2018Jun 6, 2027phase 3 · NCT05329649
Cajal Therapeutics22 open or runningphase 1since Oct 22, 2026May 5, 2026Oct 2027phase 1 · NCT07901933

Also a collaborator on its studies: CRISPR Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2018First study: phase 3 study in beta-ThalassemiaNew to Vertex PharmaceuticalsVertex Pharmaceuticals · NCT03655678 · 59 enrolled · United States, Canada, Germany and more
  2. Nov 9, 2018Phase 3 study in Anemia, Sickle CellVertex Pharmaceuticals · NCT03745287 · 63 enrolled · United States, Belgium, Canada and more
  3. Dec 20, 2019Phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT04208529 · 160 planned · United States, Belgium, Canada and more
  4. Apr 7, 20222 phase 3 studiesVertex Pharmaceuticals · NCT05356195, NCT05329649
  5. Jul 26, 2022Phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT05477563 · 26 planned · United States, Germany, Italy and more
  6. Jun 23, 2023Phase 3 study in Anemia, Sickle CellVertex Pharmaceuticals · NCT05951205
  7. May 5, 2026Cajal Therapeutics’ first study: early phase 1 study in AnemiaNew to Cajal TherapeuticsCajal Therapeutics · NCT07577817 · 72 planned · Australia
  8. Oct 22, 2026Phase 1 study in Renal Insufficiency, ChronicCajal Therapeutics · NCT07901933 · 24 planned · Australia

Ahead

  1. Jun 6, 2027Primary completion: phase 3 study in Anemia, Sickle CellVertex Pharmaceuticals · NCT05329649
  2. Jun 9, 2027Primary completion: phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT05477563
  3. Oct 2027Primary completion: phase 1 study in Renal Insufficiency, ChronicCajal Therapeutics · NCT07901933
  4. Nov 14, 2027Primary completion: phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT05356195

TargetBeta

BCL11A →read by rule
“B-cell lymphoma/leukemia 11A gene editing negative modulator”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07901933Renal Insufficiency, Chronic · Australia1Not yet recruitingCajal TherapeuticsOct 202724
NCT07577817Anemia · AustraliaEarly 1RecruitingCajal TherapeuticsOct 202672
NCT05951205Anemia, Sickle Cell3WithdrawnVertex PharmaceuticalsDec 31, 20330
NCT05477563beta-Thalassemia · United States, Germany, Italy and more3RecruitingVertex PharmaceuticalsJun 9, 202726
NCT05356195beta-Thalassemia · United States, Canada, Germany and more3Active, not recruitingVertex PharmaceuticalsNov 14, 202716
NCT05329649Anemia, Sickle Cell · United States, Germany, Italy and more3Active, not recruitingVertex PharmaceuticalsJun 6, 202713
NCT04208529beta-Thalassemia · United States, Belgium, Canada and more3By invitationVertex PharmaceuticalsSep 30, 2039160
NCT03745287Anemia, Sickle Cell · United States, Belgium, Canada and more3CompletedVertex PharmaceuticalsJul 7, 202563
NCT03655678beta-Thalassemia · United States, Canada, Germany and more3CompletedVertex PharmaceuticalsNov 13, 202559

How it is read

Names in the registry

  • “CTX001”, 6 entries
  • “Exa-cel”, 2 entries
  • “CTX001 With and Without Iron”, 1 entry
  • “CTX001 With Iron”, 1 entry
  • “CTX001 Multiple Dose”, 1 entry

Codes read as this program: CTX001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.